title: Return of fertility following discontinuation of Norplant-II subdermal implants. ICMR Task Force on Hormonal Contraception.
abstract: A total of 627 women who had discontinued the use of the Norplant-II implants for various reasons and were exposed to the risk of pregnancy were followed-up for two years for return of fertility. The cumulative conception rates in women who had discontinued due to planning pregnancy were 80.3 per 100 women at one year and 88.3 per 100 women at two years. The majority of women who did conceive (90 percent), had full-term normal live births; about 4 percent of women had spontaneous abortions, the remaining 6 percent decided on elective termination of pregnancy (ETP). The cumulative conception rates in women who discontinued due to bleeding irregularities and 'other reasons' were 64.5 and 55.8 per 100 women at one year and 77.9 and 75.1 per 100 women at two years, respectively. These rates were significantly lower as compared to those observed in women who discontinued due to planning pregnancy. A large proportion, about 40 percent, of women who conceived after discontinuation of the method due to bleeding irregularities and "other reasons," opted for ETP indicating that many women in these two groups did not desire another child and that such women need to be counselled for adopting another method of contraception. The spontaneous abortion rates observed in ex-users of Norplant-II implants (1.7 to 4.4% pregnancies) were comparable to the spontaneous abortion rates prior to Norplant-II implant use (3.6% pregnancies) indicating that ex-users of Norplant-II implants were not at a higher risk of spontaneous abortion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Human Resource Development Research, Indian Council of Medical Research, Ansari Nagar, New Delhi.
authors.forename: K
authors.initials: K
authors.lastname: Buckshee
authors.forename: P
authors.initials: P
authors.lastname: Chatterjee
authors.forename: G I
authors.initials: GI
authors.lastname: Dhall
authors.forename: M N
authors.initials: MN
authors.lastname: Hazra
authors.forename: B S
authors.initials: BS
authors.lastname: Kodkany
authors.forename: K
authors.initials: K
authors.lastname: Lalitha
authors.forename: A
authors.initials: A
authors.lastname: Logambal
authors.forename: P
authors.initials: P
authors.lastname: Manchanda
authors.forename: U K
authors.initials: UK
authors.lastname: Nanda
authors.forename: G
authors.initials: G
authors.lastname: RaiChoudhury
mesh_terms: D000328:Adult; D000375:Aging; D004343:Drug Implants; D005260:Female; D005298:Fertility; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D008598:Menstruation; D011247:Pregnancy; D011256:Pregnancy Outcome
chemical_list: D004343:Drug Implants; D016912:Levonorgestrel